Sight Sciences Pitches $150M IPO for Its Glaucoma, Dry Eye Devices
07/09/2021
Sight Sciences hopes to see its way to nearly a $1 billion valuation through a $150 million Nasdaq IPO, according to a Fierce Biotech report.
By going public, the Menlo Park, California-based company hopes to fund ongoing and future clinical trials for both of its marketed systems as well as other R&D and commercial efforts, according to a prospectus filed with the Securities and Exchange Commission.